Is oral immunotherapy the cure for food allergies?
OBJECTIVE
To review current evidence on food oral immunotherapy (OIT).


RESULTS
Desensitized state, defined as the ingestion of a substantial amount of food in the home diet that protects from severe reactions to accidental exposures, can be achieved by approximately 50-75% of the children treated with OIT. The rate of permanent tolerance is unknown; the longer duration of OIT may result in permanent tolerance. Side effects are common both during the initial dose escalation and during home dosing. Most reactions are mild (oral pruritus, abdominal discomfort, and rashes) and decrease in frequency with the longer duration of OIT. Severe reactions treated with epinephrine have been reported during home dosing. Factors associated with increased risk of reactions to previously tolerated doses during home dosing include exercise, viral infection, dosing on empty stomach, menses, and asthma exacerbation.


CONCLUSIONS
These preliminary data on OIT are encouraging. Additional studies must answer multiple questions including optimal dose, ideal duration of oral/sublingual immunotherapy, degree of protection, efficacy for different ages, severity and type of food allergy responsive to treatment and need for patient protection during home administration. Until these questions are answered in rigorous multicenter randomized and placebo-controlled trials, OIT remains an experimental approach with not sufficiently well established risk-to-benefit ratio.
Nowak-Wegrzyn
Anna
A
Jaffe Food Allergy Institute and Department of Pediatrics, Mount Sinai School of Medicine, New York, NY 10029, USA. anna.nowak-wegrzyn@mssm.edu
Fiocchi
Alessandro
A
D000284:Administration, Oral; D000485:Allergens / Q000008:administration & dosage* / Q000009:adverse effects; D003888:Desensitization, Immunologic; D004837:Epinephrine / Q000627:therapeutic use; D005076:Exanthema / Q000188:drug therapy / Q000209:etiology; D005512:Food Hypersensitivity / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007108:Immune Tolerance; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology; D018570:Risk Assessment
D000485:Allergens; D004837:Epinephrine